Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > LATEST
LATEST
-
ARCHIVE Novo Nordisk Aims at Top Position in 3 Fields: Mr Eilersen
March 19, 2007
-
ARCHIVE MEDICAL FACILITIES&NURSING CARE NEWS IN BRIEF
March 19, 2007
-
ARCHIVE Nippon Shinyaku Aims at 3% Growth in Mid, Long Term
March 19, 2007
-
ARCHIVE New Q&A Issued on Strengths of Generics
March 19, 2007
-
ARCHIVE NBI's Training System Boosts MR Productivity
March 19, 2007
-
ARCHIVE Ain Pharamaciez to Sell Generics Outside Group from April
March 19, 2007
-
ARCHIVE BUSINESS NEWS IN BRIEF
March 19, 2007
-
ARCHIVE MEDICAL DEVICE NEWS IN BRIEF
March 19, 2007
-
ARCHIVE 7 APIs Including Celecoxib to Be Included in NHI Price List
March 19, 2007
-
ARCHIVE Efficacy of Narcotic Analgesics Predicted by Gene Polymorphisms
March 19, 2007
-
ARCHIVE Gov't-Private Sector Dialogueto Be Held on Distribution
March 19, 2007
-
ARCHIVE Consider Licensing, Not Independent Marketing, in Advanced Countries: Mr Seko
March 19, 2007
-
ARCHIVE Warning against Exacerbation of Hepatitis Added to Package Insert of Rituximab
March 19, 2007
-
ARCHIVE Amended PAL Presents Opportunities: JACDS
March 19, 2007
-
ARCHIVE REGULATORY NEWS IN BRIEF
March 19, 2007
-
ARCHIVE 6-Year Education Makes Schools of Pharmacy Less Attractive: Survey
March 19, 2007
-
ARCHIVE PMDA to Hire 236 New Reviewers by End of FY2009
March 19, 2007
-
ARCHIVE Global Sales of 3 New Strategic Products to Exceed US$1.5 Bil. Each: Mr Naito
March 19, 2007
-
ARCHIVE Lactoferrin Improves Dyslipidemia: Lion
March 19, 2007
-
ARCHIVE Seretide Reduces Risk of Death in COPD: GSK
March 19, 2007
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…